255 related articles for article (PubMed ID: 15165849)
1. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
2. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.
Benedetti P; Fiorani P; Capuani L; Wang JC
Cancer Res; 1993 Sep; 53(18):4343-8. PubMed ID: 8395982
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
5. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
6. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
8. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
Staker BL; Feese MD; Cushman M; Pommier Y; Zembower D; Stewart L; Burgin AB
J Med Chem; 2005 Apr; 48(7):2336-45. PubMed ID: 15801827
[TBL] [Abstract][Full Text] [Related]
9. Role of flexibility and long range communication on the function of human topoisomerase I.
Chillemi G; Fiorani P; Bruselles A; Castelli S; Campagna A; Sarra O; Tesauro C; Fiorentini M; Vassallo O; D'Annessa I; Santoleri S; Desideri A
Ital J Biochem; 2007 Jun; 56(2):110-4. PubMed ID: 17722651
[TBL] [Abstract][Full Text] [Related]
10. Persistence of camptothecin analog-topoisomerase I-DNA ternary complexes: a molecular dynamics study.
Siu FM; Che CM
J Am Chem Soc; 2008 Dec; 130(52):17928-37. PubMed ID: 19035632
[TBL] [Abstract][Full Text] [Related]
11. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori A; Harker WG; Kohlhagen G; Hoki Y; Pommier Y
Cancer Res; 1995 Mar; 55(6):1339-46. PubMed ID: 7882333
[TBL] [Abstract][Full Text] [Related]
12. Effects of camptothecin analogues on DNA transformations mediated by calf thymus and human DNA topoisomerases I.
Wang X; Short GF; Kingsbury WD; Johnson RK; Hecht SM
Chem Res Toxicol; 1998 Nov; 11(11):1352-60. PubMed ID: 9815197
[TBL] [Abstract][Full Text] [Related]
13. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis.
Lisby M; Krogh BO; Boege F; Westergaard O; Knudsen BR
Biochemistry; 1998 Jul; 37(30):10815-27. PubMed ID: 9692972
[TBL] [Abstract][Full Text] [Related]
14. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
Garcia-Carbonero R; Supko JG
Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
[TBL] [Abstract][Full Text] [Related]
15. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
Tsao YP; Russo A; Nyamuswa G; Silber R; Liu LF
Cancer Res; 1993 Dec; 53(24):5908-14. PubMed ID: 8261402
[TBL] [Abstract][Full Text] [Related]
16. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
Fujimori A; Hoki Y; Popescu NC; Pommier Y
Oncol Res; 1996; 8(7-8):295-301. PubMed ID: 8938793
[TBL] [Abstract][Full Text] [Related]
17. Antitumour drugs impede DNA uncoiling by topoisomerase I.
Koster DA; Palle K; Bot ES; Bjornsti MA; Dekker NH
Nature; 2007 Jul; 448(7150):213-7. PubMed ID: 17589503
[TBL] [Abstract][Full Text] [Related]
18. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.
Urasaki Y; Laco G; Takebayashi Y; Bailly C; Kohlhagen G; Pommier Y
Cancer Res; 2001 Jan; 61(2):504-8. PubMed ID: 11212241
[TBL] [Abstract][Full Text] [Related]
19. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
20. The structure of the transition state of the heterodimeric topoisomerase I of Leishmania donovani as a vanadate complex with nicked DNA.
Davies DR; Mushtaq A; Interthal H; Champoux JJ; Hol WG
J Mol Biol; 2006 Apr; 357(4):1202-10. PubMed ID: 16487540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
